US009636319B1

(12) **United States Patent**
Vaughn et al.

(10) **Patent No.: US 9,636,319 B1**
(45) **Date of Patent: *May 2, 2017**

(54) **FUMARATE ESTER DOSAGE FORMS**

(71) Applicant: **BANNER LIFE SCIENCES LLC**, High Point, NC (US)

(72) Inventors: **Jason M. Vaughn**, Browns Summit, NC (US); **Justin R. Hughey**, Asheboro, NC (US); **Tanesha Roberts**, Greensboro, NC (US); **Tatyana Dyakonov**, Greensboro, NC (US); **Sunil Agnihotri**, Scarborough, ME (US); **Aqeel A. Fatmi**, High Point, NC (US)

(73) Assignee: **BANNER LIFE SCIENCES LLC**, High Point, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/386,133**

(22) Filed: **Dec. 21, 2016**

Related U.S. Application Data

(63) Continuation of application No. 15/248,506, filed on Aug. 26, 2016, which is a continuation-in-part of application No. 14/840,072, filed on Aug. 31, 2015, now Pat. No. 9,326,947, and a continuation-in-part of application No. PCT/US2015/047636, filed on Aug. 31, 2015.

(60) Provisional application No. 62/300,941, filed on Feb. 29, 2016, provisional application No. 62/356,872, filed on Jun. 30, 2016.

(51) **Int. Cl.**

A61K 8/04	(2006.01)
A61K 9/48	(2006.01)
A61K 47/44	(2017.01)
A61K 8/37	(2006.01)
A61K 31/225	(2006.01)
A61K 9/00	(2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/225*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 9/4858*** (2013.01); ***A61K 9/4866*** (2013.01); ***A61K 9/4891*** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,146,730	A	9/1992	Dietel	
5,424,332	A	6/1995	Speiser	
5,459,983	A	10/1995	Dietel	
6,355,676	B1	3/2002	Joshi	
6,436,992	B1	8/2002	Joshi	
6,482,516	B1	11/2002	Dietel	
6,509,376	B1	1/2003	Joshi	
7,157,423	B2	1/2007	Joshi	
7,320,999	B2	1/2008	Joshi	
7,432,240	B2	10/2008	Joshi	
7,612,110	B2	11/2009	Joshi	
7,619,001	B2	11/2009	Joshi	
7,803,840	B2	9/2010	Joshi	
7,915,310	B2	3/2011	Joshi et al.	
8,293,270	B2	10/2012	Sukuru	
8,333,989	B2	12/2012	Sukuru	
8,399,514	B2	3/2013	O'Neill et al.	
8,524,773	B2	9/2013	Joshi	
8,669,281	B1	3/2014	Sanrame	
8,669,282	B2	3/2014	Zicker	
8,685,445	B2	4/2014	Hassan	
8,759,393	B2	6/2014	Joshi	
9,090,558	B2	7/2015	Sanrame	
9,326,947	B1 *	5/2016	Dyakonov	A61K 9/4875
9,326,965	B2 *	5/2016	Dyakonov	A61K 31/225
9,511,043	B2 *	12/2016	Dyakonov	A61K 31/225
9,517,209	B2 *	12/2016	Dyakonov	A61K 9/4875
2003/0018072	A1	1/2003	Joshi	
2004/0054001	A1 *	3/2004	Joshi	A61K 9/1652 514/527
2006/0051345	A1	3/2006	Frohna	
2006/0115527	A1	6/2006	Chidambaram	
2006/0165778	A1	7/2006	Hassan	
2007/0104778	A1	5/2007	Ketsela	
2008/0004344	A1	1/2008	Nilsson	
2008/0233185	A1	9/2008	Joshi	
2008/0299196	A1	12/2008	Nilsson	
2008/0300217	A1	12/2008	Nilsson	
2009/0304790	A1	12/2009	Nilsson	
2010/0034274	A1	2/2010	Li	

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0312697	A2	4/1989
WO	0030622	A2	6/2000
WO	02055063	A2	7/2002
WO	02055066	A1	7/2002
WO	02055067	A2	7/2002

(Continued)

OTHER PUBLICATIONS

Tecfidera® Prescribing Information Mar. 2013 (Biogen Idec).
Sheikh et al., "Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers," Clinical Therapeutics 35(10): 1582-1594 (2013).

(Continued)

Primary Examiner — Abigail Fisher
(74) *Attorney, Agent, or Firm* — Brinks Gilson & Lione

(57) **ABSTRACT**

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.

20 Claims, 25 Drawing Sheets